Skip to main content

PLUS THERAPEUTICS, Inc. (PSTV) Stock

PLUS THERAPEUTICS, Inc. Stock Details, Movements and Public Alerts

Stock Details

PLUS THERAPEUTICS, Inc. (PSTV), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NCM.Currently, the stock is trading at $1.64. Over the past 52 weeks, it has ranged between $2.90 and $23.43. This places the current price at 7.0% of its 52-week high and -43.4% above its 52-week low. Recent trading volume was recorded at 61,774. The 14-day Relative Strength Index (RSI) stands at 38.54, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $2.27 by 27.75%. Similarly, it is below its 200-day moving average of $4.89 by 66.46%. The MACD histogram is 0.04, indicating bullish momentum (MACD Line: -0.16, Signal Line: -0.20). There is currently 1 active alert set for PSTV by users.

52-Week Range

$23.43 - $2.90

-93.00% from high · +-43.45% from low

Avg Daily Volume

168,968

20-day average

100-day avg: 135,975

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

0.18

Below market average

Forward P/E

-1.62

Earnings expected to grow

PEG Ratio

2.45

Potentially overvalued

Price to Book

2.22

EV/EBITDA

-0.66

EPS (TTM)

$21.56

Price to Sales

5.14

Beta

1.42

Similar volatility to market

Q:How is PSTV valued relative to its earnings and growth?
PLUS THERAPEUTICS, Inc. trades at a P/E ratio of 0.18, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong. Looking ahead, the forward P/E of -1.62 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 2.45 indicates a premium valuation even accounting for growth.
Q:What is PSTV's risk profile compared to the market?
With a beta of 1.42, PLUS THERAPEUTICS, Inc. is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 2.22 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-230.24%

Operating Margin

-692.51%

EBITDA

$-18,486,000

Return on Assets

-73.82%

Revenue Growth (YoY)

-2.90%

Q:How profitable and efficient is PSTV's business model?
PLUS THERAPEUTICS, Inc. achieves a profit margin of -230.24%, meaning it retains $-230.24 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -692.51% reveals how efficiently the company runs its core business operations before interest and taxes.
Q:What are PSTV's recent growth trends?
PLUS THERAPEUTICS, Inc.'s revenue declined by 2.90% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$26.6M

Revenue (TTM)

$5.18M

Revenue/Share (TTM)

$1.12

Shares Outstanding

6.88M

Book Value/Share

$1.74

Asset Type

EQUITY

Q:What is PSTV's market capitalization and position?
PLUS THERAPEUTICS, Inc. has a market capitalization of $26.6M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 6.88M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does PSTV's price compare to its book value?
PLUS THERAPEUTICS, Inc.'s book value per share is $1.74, while the current stock price is $1.64, resulting in a price-to-book (P/B) ratio of 0.94. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$36.00

2095.12% upside potential

Analyst Recommendations

Strong Buy

1

Buy

3

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for PSTV?
4 analysts cover PSTV with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $36.00 implies 2095.1% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on PSTV?
Current analyst recommendations:1 Strong Buy, 3 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 3, 2026, 02:12 AM

Technical Indicators

RSI (14-day)

38.54

Neutral

50-Day Moving Average

$2.27

-27.75% below MA-50

200-Day Moving Average

$4.89

-66.46% below MA-200

MACD Line

-0.16

MACD Signal

-0.20

MACD Histogram

0.04

Bullish

Q:What does PSTV's RSI value tell investors?
The RSI (Relative Strength Index) for PSTV is currently 38.54, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret PSTV's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.16 above the signal line at -0.20, with histogram at 0.04. This bullish crossover suggests upward momentum is building. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($2.27) is below the 200-day MA ($4.89), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Oct 24, 2026, 01:14 AM

Active Alerts

Alert Condition
MA Breakout (Bullish)
Threshold
50 days
Created
Oct 12, 2026, 04:15 PM

Stay Ahead of the Market with PLUS THERAPEUTICS, Inc. Alerts

Set up price alerts for PLUS THERAPEUTICS, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.